Eli Lilly Stock News & Updates
[WKN: 858560 | Symbol: LLY]
Eli Lilly – Why the Stock Rally May Not Be Over Yet!
For me, Eli Lilly (LLY) remains one of the most exciting leader stocks in the healthcare sector following...
Advantage in the Billion-Dollar Market: China Approves Eli Lilly's First Weight-Loss Pill
First-Mover Advantage in China: The Chinese drug regulatory authority grants market approval to the...
Untapped Markets: Jefferies Believes Eli Lilly's Global GLP-1 Potential is Still Underestimated
More Optimistic Price Target: Jefferies raises the target price for Eli Lilly to $1.700 and reaffirms...
GLP-1 Dynamics Continue: Eli Lilly Significantly Raises Revenue Forecast After Strong Quarter
Operational Record Numbers: In the third quarter, the company’s revenue rose to $24.4 billion,...
Lula wins fourth term - Musk warns of credit crunch in AI sector - Eli Lilly lung cancer drug delivers encouraging study data - SoftBank plans multi-billion-dollar AI offensive in Malaysia
On Friday, October 23, 2026, US stock markets closed the week with losses after a volatile trading session....
Eli Lilly – Foundayo before EU approval: New opportunities in the global USD 114 billion weight loss boom
The EMA recommends Foundayo for obesity and type 2 diabetes. A EU launch is still possible in 2026....
Eli Lilly – Why I Prefer Lilly Over Novo Nordisk After the Attempted Breakout
The rotation from technology stocks to the healthcare sector makes Eli Lilly (LLY) an interesting prospect...
Lead in the Billion-Dollar Weight-Loss Pill Market! Eli Lilly Keeps Rival Novo Nordisk at Bay!
Market dominance in seniors: Eli Lilly captures 70% of approximately 700,000 Medicare patients newly...
Eli Lilly: FDA Approval for Mounjaro for Cardiovascular Prevention Opens New Billion-Dollar Markets
Mounjaro and Zepbound drove a revenue growth of 48% to $23.0 billion in the second quarter. The...
Eli Lilly: Cost Advantages in Obesity Therapy Secure Reimbursement Prospects for the Healthcare System
Zepbound reduces monthly costs for patients aged 55 and older by up to $607. Reduced hospital stays...
Eli Lilly: GLP-1 Market Leader Grows by 48% in Record Quarter - Stock Near All-Time High!
The second quarter impresses with a revenue growth of 48%. Mounjaro and Zepbound set a revenue record...